Goldman Sachs Group Inc Caribou Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 822,840 shares of CRBU stock, worth $987,408. This represents 0.0% of its overall portfolio holdings.

Number of Shares
822,840
Previous 822,840 -0.0%
Holding current value
$987,408
Previous $748,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$0.88 - $1.88 $217,972 - $465,668
-247,696 Reduced 23.14%
822,840 $748,000
Q4 2024

Feb 11, 2025
BUY
$1.59 - $2.79 $587,733 - $1.03 Million
369,644 Added 52.74%
1,070,536 $1.7 Million
Q3 2024

Nov 14, 2024
SELL
$1.56 - $2.73 $761,080 - $1.33 Million
-487,872 Reduced 41.04%
700,892 $1.37 Million
Q2 2024

Aug 13, 2024
BUY
$1.62 - $5.05 $949,096 - $2.96 Million
585,862 Added 97.17%
1,188,764 $1.95 Million
Q1 2024

May 15, 2024
SELL
$4.82 - $8.26 $275,405 - $471,959
-57,138 Reduced 8.66%
602,902 $3.1 Million
Q4 2023

Feb 13, 2024
BUY
$3.58 - $6.25 $946,662 - $1.65 Million
264,431 Added 66.84%
660,040 $3.78 Million
Q3 2023

May 14, 2024
SELL
$4.08 - $8.14 $1.08 Million - $2.15 Million
-264,431 Reduced 40.06%
395,609 $1.89 Million
Q3 2023

Nov 14, 2023
BUY
$4.08 - $8.14 $509,869 - $1.02 Million
124,968 Added 46.17%
395,609 $1.89 Million
Q2 2023

May 14, 2024
SELL
$4.04 - $5.47 $174,237 - $235,910
-43,128 Reduced 13.75%
270,641 $1.15 Million
Q2 2023

Aug 14, 2023
SELL
$4.04 - $5.47 $174,237 - $235,910
-43,128 Reduced 13.75%
270,641 $1.15 Million
Q1 2023

May 14, 2024
SELL
$4.3 - $7.78 $168,250 - $304,415
-39,128 Reduced 11.09%
313,769 $1.67 Million
Q1 2023

May 11, 2023
SELL
$4.3 - $7.78 $168,250 - $304,415
-39,128 Reduced 11.09%
313,769 $1.67 Million
Q4 2022

May 14, 2024
SELL
$5.57 - $11.01 $1.2 Million - $2.37 Million
-215,432 Reduced 37.91%
352,897 $2.22 Million
Q4 2022

Feb 13, 2023
SELL
$5.57 - $11.01 $1.2 Million - $2.37 Million
-215,432 Reduced 37.91%
352,897 $2.22 Million
Q3 2022

May 14, 2024
BUY
$5.34 - $12.79 $2.29 Million - $5.47 Million
428,011 Added 305.03%
568,329 $6 Million
Q3 2022

Nov 10, 2022
BUY
$5.34 - $12.79 $2.29 Million - $5.47 Million
428,011 Added 305.03%
568,329 $6 Million
Q2 2022

May 14, 2024
SELL
$5.1 - $9.74 $2.65 Million - $5.06 Million
-519,722 Reduced 78.74%
140,318 $761,000
Q2 2022

Aug 15, 2022
SELL
$5.1 - $9.74 $709,614 - $1.36 Million
-139,140 Reduced 49.79%
140,318 $761,000
Q1 2022

May 16, 2022
BUY
$8.42 - $15.32 $2.09 Million - $3.8 Million
247,735 Added 780.93%
279,458 $2.57 Million
Q4 2021

Feb 14, 2022
BUY
$14.59 - $23.26 $462,838 - $737,876
31,723 New
31,723 $478,000

Others Institutions Holding CRBU

# of Institutions
136
Shares Held
47.1M
Call Options Held
17.1K
Put Options Held
58.1K
View Full List

About Caribou Biosciences, Inc.

CRBU Quotes by TradingView
  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $73M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email